Sana Biotechnology (SANA) Invested Capital (2021 - 2026)

Sana Biotechnology (SANA) has 5 years of Invested Capital data on file, last reported at $53.6 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital changed N/A year-over-year to $53.6 million; the trailing twelve-month figure through Mar 2026 stood at $93.8 million (changed N/A YoY), and the FY2025 full-year result was $40.2 million, changed N/A from the prior year.
• Invested Capital advanced to $53.6 million in Q1 2026, from $40.2 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $59.4 million in Q3 2022 to a low of $40.2 million in Q4 2025.
• A 4-year average of $53.3 million and a median of $54.5 million in 2022 frame the typical range for Invested Capital.
• Peak annual rise in Invested Capital reached 36.75% in 2022, while the deepest fall reached 7.71% in 2022.
• Tracing SANA's Invested Capital over 4 years: stood at $55.3 million in 2022, then climbed by 5.55% to $58.4 million in 2023, then slumped by 31.18% to $40.2 million in 2025, then soared by 33.22% to $53.6 million in 2026.
• Business Quant data shows SANA's Invested Capital at $53.6 million in Q1 2026, $40.2 million in Q4 2025, and $58.4 million in Q2 2023.